EP1576125A4 - Aktivierung von hcv-spezifischen zellen - Google Patents

Aktivierung von hcv-spezifischen zellen

Info

Publication number
EP1576125A4
EP1576125A4 EP03781368A EP03781368A EP1576125A4 EP 1576125 A4 EP1576125 A4 EP 1576125A4 EP 03781368 A EP03781368 A EP 03781368A EP 03781368 A EP03781368 A EP 03781368A EP 1576125 A4 EP1576125 A4 EP 1576125A4
Authority
EP
European Patent Office
Prior art keywords
hcv
activation
specific cells
cells
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03781368A
Other languages
English (en)
French (fr)
Other versions
EP1576125A2 (de
Inventor
Michael Houghton
Steve Coates
Mark Selby
Xavier Paliard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of EP1576125A2 publication Critical patent/EP1576125A2/de
Publication of EP1576125A4 publication Critical patent/EP1576125A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP03781368A 2002-10-25 2003-10-24 Aktivierung von hcv-spezifischen zellen Withdrawn EP1576125A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28134102A 2002-10-25 2002-10-25
US281341 2002-10-25
PCT/US2003/033610 WO2004039950A2 (en) 2002-10-25 2003-10-24 Activation of hcv-specific cells

Publications (2)

Publication Number Publication Date
EP1576125A2 EP1576125A2 (de) 2005-09-21
EP1576125A4 true EP1576125A4 (de) 2008-09-03

Family

ID=32228760

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03781368A Withdrawn EP1576125A4 (de) 2002-10-25 2003-10-24 Aktivierung von hcv-spezifischen zellen

Country Status (4)

Country Link
EP (1) EP1576125A4 (de)
AU (1) AU2003287188A1 (de)
CA (1) CA2505611A1 (de)
WO (1) WO2004039950A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
CA2523266A1 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
NZ551319A (en) * 2004-05-17 2010-07-30 Novartis Vaccines & Diagnostic Truncated Hepatitis C virus NS5 domain and fusion proteins comprising same
KR100958505B1 (ko) * 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
WO2008024518A2 (en) 2006-08-25 2008-02-28 Novartis Ag Hcv fusion polypeptides
WO2011163558A1 (en) * 2010-06-25 2011-12-29 Abbott Laboratories Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
CN103819565B (zh) * 2014-02-26 2016-11-09 广州万孚生物技术股份有限公司 Hcv重组融合抗原及其表达基因和制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044469A2 (en) * 1996-05-24 1997-11-27 Chiron Corporation Multiple epitope fusion protein
WO2004005473A2 (en) * 2002-07-02 2004-01-15 Chiron Corporation Hcv fusion proteins with modified ns3 domains

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US6153378A (en) * 1992-10-16 2000-11-28 Bionova Corporation Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044469A2 (en) * 1996-05-24 1997-11-27 Chiron Corporation Multiple epitope fusion protein
WO2004005473A2 (en) * 2002-07-02 2004-01-15 Chiron Corporation Hcv fusion proteins with modified ns3 domains

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LECHNER FRANZISKA ET AL: "Analysis of successful immune responses in persons infected with hepatitis C virus", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 191, no. 9, 1 May 2000 (2000-05-01), pages 1499 - 1512, XP002489353, ISSN: 0022-1007 *
SUHRBIER ANDREAS: "Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes.", EXPERT REVIEW OF VACCINES AUG 2002, vol. 1, no. 2, August 2002 (2002-08-01), pages 207 - 213, XP008094488, ISSN: 1476-0584 *
VAJDY M ET AL: "Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 87, no. 8, 27 July 2006 (2006-07-27), pages 2253 - 2262, XP002467874, ISSN: 0022-1317 *

Also Published As

Publication number Publication date
EP1576125A2 (de) 2005-09-21
WO2004039950A2 (en) 2004-05-13
CA2505611A1 (en) 2004-05-13
WO2004039950A3 (en) 2007-11-22
AU2003287188A8 (en) 2004-05-25
AU2003287188A1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
DE60318920D1 (de) Induktion von Insulin-produzierende Zellen
EP1537585A4 (de) Speicherzelle
EP1674473A4 (de) Generator von photosäure
SI1897548T2 (sl) Regulacija celic T
NO20034702D0 (no) Elektrode
EP1490864A4 (de) Intelligente persönliche assistenzen
FI20031885L (fi) Sähkökäytön energiakulutus
DE60311517D1 (de) Multiionophore membranelektrode
DE60322351D1 (de) Reaktionszelle
DE60307556D1 (de) Verbindungsstruktur von Verbindern
DE60323571D1 (de) Wasseraktivierbarer Klebstoff
EP1576125A4 (de) Aktivierung von hcv-spezifischen zellen
EP1981537A4 (de) Aktivierung von hcv-spezifischen t-zellen
DE502004008433D1 (de) Wägezelle
DE60318401D1 (de) Hydrierung von terephthalsäurerestehaltigen polyesteroligomeren
DE10393352D2 (de) Skalpell
ATA7862002A (de) Wasserauslaufbatterie
ATE375323T1 (de) Festkörper-synthese von lithium-meta-arsenit
ATE404661T1 (de) Transdifferenzierung von pankreas- acinuszellen
DE502004006136D1 (de) Verrastung von Baugruppen
DE602005012014D1 (de) Wiederverwertung von Batterien
SE0302280D0 (sv) Cells
NO20022617D0 (no) Anode
ITPV20020001A1 (it) Termodinamo elettrochimica
FI6126U1 (fi) Avoimen rakentamisen tehokas toteuttaminen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050525

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080902

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/005 20060101ALI20071207BHEP

Ipc: A61K 39/385 20060101ALI20071207BHEP

Ipc: A61K 39/29 20060101AFI20071207BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080804

17Q First examination report despatched

Effective date: 20090210

18D Application deemed to be withdrawn

Effective date: 20110204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20110405

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1080902

Country of ref document: HK